Pediatrix Medical Group financials
$26.06+0.50%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $487.8M | $476.2M | $493.8M | $492.9M | $468.8M | $458.4M | $502.4M | $511.2M | $504.3M | $495.1M | $496.4M | $506.6M |
| Gross profit | $487.8M | $476.2M | $493.8M | $492.9M | $468.8M | $458.4M | $502.4M | $511.2M | $504.3M | $495.1M | $496.4M | $506.6M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | $56.9M | $41.7M | $48.8M | $68.1M | $59.9M | $32.1M | $38.1M | $33.9M | -$146.8M | $15.9M | -$131.5M | $40.3M |
| Net income | $39.8M | $29.6M | $33.7M | $71.7M | $39.3M | $20.7M | $30.5M | $19.4M | -$153.0M | $4.0M | -$124.3M | $21.4M |
| Net margin | 8.2% | 6.2% | 6.8% | 14.5% | 8.4% | 4.5% | 6.1% | 3.8% | −30.3% | 0.8% | −25.0% | 4.2% |
| Diluted EPS | $0.49 | $0.36 | $0.40 | $0.84 | $0.46 | $0.24 | $0.37 | $0.23 | $-1.84 | $0.05 | $-1.54 | $0.26 |
| EBITDA | $71.2M | $52.7M | $60.3M | $79.6M | $69.0M | $44.0M | $65.0M | $58.7M | $57.6M | $34.7M | $39.0M | $49.5M |
| Operating cash flow | $125.3M | -$129.8M | $114.1M | $137.3M | $137.2M | -$117.5M | $133.0M | $91.8M | $107.0M | -$125.2M | $69.3M | $79.9M |
| Free cash flow | $123.9M | -$136.1M | $108.8M | $131.9M | $132.7M | -$120.8M | $129.6M | $85.5M | $100.0M | -$130.6M | $60.2M | $70.8M |
| Diluted shares | 81.4M | 83.1M | 84.5M | 85.6M | 85.5M | 85.4M | 82.2M | 84.5M | 83.3M | 83.3M | 80.9M | 83.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $288.9M | $205.8M | $375.2M | $340.1M | $224.7M | $99.0M |
| Short-term investments | $115.3M | $123.2M | $124.5M | $123.0M | $123.6M | $120.2M |
| Total debt | $584.2M | $590.8M | $597.3M | $602.5M | $607.5M | $612.6M |
| Total assets | $2.13B | $2.07B | $2.25B | $2.20B | $2.10B | $1.99B |
| Total liabilities | $1.25B | $1.19B | $1.38B | $1.31B | $1.27B | $1.20B |
| Shareholders' equity | $881.0M | $878.6M | $865.9M | $890.7M | $833.8M | $789.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology